Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT 2: LY2963016 vs Lantus in Type 2 Diabetes
NCT01421459Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Primary completion
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Started Sep 2011; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01421459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421459.